Clinical Trial Update: PRISM Study-Pruritus Relief Through Itch Scratch Modulation [Phase 2, Phase 3]

View source ↗

Summary

The PRISM study evaluated pruritus relief through itch-scratch modulation in prurigo nodularis and has completed Phase 2/3. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Haduvio (nalbuphine extended-release)

Snippet

Sponsor: Trevi Therapeutics | Conditions: Prurigo Nodularis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-06-24